ATEC — Alphatec Holdings, Inc.

ATEC Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $197 million, up 30% year-over-year and up $11 million sequentially.
• Surgical Revenue: $177 million, representing a 31% increase year-over-year and a 5% sequential increase.
• Adjusted EBITDA: $26 million, or 13% of revenue, marking an 840 basis point improvement from the prior year.
• Free Cash Flow: Positive $5 million, with a trailing 12-month adjusted EBITDA of $81 million.
• Cash Position: Ended the quarter with $156 million in cash and $60 million available on a credit line, totaling $216 million in cash and available liquidity.

2. Strategic Updates and Business Highlights:

• ATEC reported strong same-store sales growth of 30% in established territories, indicating robust demand.
• New surgeon adoption increased by 26%, reflecting the attractiveness of ATEC's portfolio and investments in sales talent.
• The company emphasized its 100% focus on spine, with a strategic push towards proceduralization, particularly in lateral and cervical solutions.
• ATEC is in the early stages of expanding its influence in the deformity market, driven by the EOS platform and upcoming product launches.
• The company highlighted the integration of technology in surgical procedures, aiming to improve outcomes and democratize access to advanced surgical techniques.

3. Forward Guidance and Outlook:

• ATEC raised its full-year revenue guidance by $18 million to $760 million, with surgical revenue expected to reach approximately $684 million.
• Adjusted EBITDA guidance for the full year is now projected at $91 million, an increase of $8 million from previous estimates.
• The company anticipates free cash flow for Q4 to range from $6 million to $8 million and expects to generate approximately $20 million in free cash flow for the next year.
• ATEC is on track to meet its long-term goal of $1 billion in revenue by 2027, with a commitment to 18% adjusted EBITDA and $65 million in free cash flow.

4. Bad News, Challenges, or Points of Concern:

• The company acknowledged the impact of expected tariffs on cost of goods sold, estimated to be in the low single-digit millions for the full year.
• There is a competitive landscape with consolidation among major players in the spine market, which could pose challenges.
• The company is cautious about the slower sequential growth expected in Q4 compared to previous years, which may reflect broader market dynamics.

5. Notable Q&A Insights:

• Management expressed confidence in future cash flow generation, with expectations of $20 million in free cash flow next year.
• There was discussion about the competitive landscape, with ATEC aiming to maintain focus on its unique procedural approach amidst market disruptions.
• The Valence system is anticipated to enhance surgical efficiency and democratize access to advanced techniques, but significant impacts are expected to materialize in 2026.
• Management emphasized the importance of surgeon adoption and the potential for continued growth, noting that established surgeons tend to increase their use of ATEC's products over time.

Overall, ATEC's Q3 2025 results reflect strong growth and profitability, with a clear strategic focus on advancing its spine solutions and expanding market share, despite facing competitive pressures and external economic factors.